Methods of transplantation and disease treatment
A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
1. A method of transplantation of cells in suspension, the method comprising:
(a) administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation; and
(b) administering said cells in suspension to the subject, wherein said cells in suspension comprise:
mesenchymal stem cells, endothelial progenitor cells and/or epithelial progenitor cells; or
hematopoietic cells which are not stem cells.
2. The method of claim 1 , wherein said mesenchymal stem cells, endothelial progenitor cells and/or epithelial progenitor cells are obtained from a fetal tissue.
3. The method of claim 1 , wherein said mesenchymal stem cells, endothelial progenitor cells and/or epithelial progenitor cells are obtained from an adult tissue.
4. The method of claim 1 , wherein said hematopoietic cells which are not stem cells comprise a subpopulation of lymphatic cells or immune cells.
5. The method of claim 4 , wherein said immune cells are selected from the group consisting of T cells, B cells, NK cells, NKT cells and dendritic cells (DCs).
6. The method of claim 5 , wherein said T cells are selected from the group consisting of CD4+ T cells, CD8+ T cells, tumor infiltrating lymphocytes (TIL) and tumor-associated lymphocytes (TALs).
7. The method of claim 1 , wherein said hematopoietic cells which are not stem cells are genetically modified.
8. The method of claim 7 , wherein said genetically modified cells comprise genetically modified immune cells.
9. The method of claim 8 , wherein said immune cells express a chimeric antigen receptor (CAR) or a modified T cell receptor (TCR).
10. The method of claim 9 , wherein said immune cells are T cells.
11. The method of claim 1 , wherein said administering to said subject a therapeutically effective amount of said anti-third party cells having said Tem phenotype is effected at least twice.
12. The method of claim 1 , wherein said subject in need of transplantation has a malignant disease.
13. The method of claim 12 , wherein said malignant disease is a solid tumor or tumor metastasis.
14. The method of claim 12 , wherein said malignant disease is a hematological malignancy.
15. The method of claim 12 , wherein said malignant disease is selected from the group consisting of a lung cancer, a leukemia, a lymphoma, a myeloma, a melanoma, a sarcoma, a neuroblastoma, a colon cancer, a colorectal cancer, a breast cancer, an ovarian cancer, an esophageal cancer, a synovial cell cancer and a pancreatic cancer.
16. The method of claim 1 , wherein said subject in need of transplantation has a non-malignant disease.
17. The method of claim 16 , wherein said non-malignant disease is selected from the group consisting of an organ dysfunction or failure, an infectious disease, an autoimmune disease and an injury.
18. The method of claim 16 , wherein said non-malignant disease is selected from the group consisting of a Parkinson's disease, an Alzheimer's disease, a multiple sclerosis, a retinal disease, a diabetes mellitus, a cerebral ischemia, a myogenic disease, a pulmonary disease, a renal disease, a hepatic disease, a cardiac disease, a gastrointestinal tract disease, a skin disease, a fertility disease and a brain disease.
19. The method of claim 16 , wherein when:
the cells are mesenchymal stem cells the disease is a medical condition selected from the group consisting of a cosmetic condition, a tissue or organ damage, an orthopedic condition, a neural condition, a heart disease or condition, a diabetes, a deafness, a Crohn's disease, an autoimmune disorder, a leukemia, a cancer, a sickle cell disease, an amyotrophic lateral sclerosis and a metabolic disorders; or
the cells are endothelial cells the disease is a medical condition selected from the group consisting of a bone disease, a bone damage, a cardiovascular disease, a cardiovascular injury, an ischemic disease, an ischemic injury, a vascular disease, a sickle cell disease, an atherosclerosis, a diabetes and an autoimmune disorder; or
the cells are epithelial cells the disease is a medical condition selected from the group consisting of a ulcer, an inflammatory bowel disease (IBD), a Crohn's disease, an ulcerative colitis, an Alzheimer's disease, a wound healing defect, a cancer, a chronic obstructive pulmonary disease (COPD), a pulmonary fibrosis, an idiopatic pulmonary fibrosis, a pulmonary hypertension, a lung cancer, a sarcoidosis, an acute lung injury (adult respiratory distress syndrome), a respiratory distress syndrome of prematurity, a chronic lung disease of prematurity (bronchopulmonary dysplasia), a surfactant protein B deficiency, a congenital diaphragmatic hernia, a pulmonary alveolar proteinosis, a pulmonary hypoplasia, a lung injury and a corneal degeneration.
20. The method of claim 4 , wherein when the hematopoietic cells which are not stem cells comprise immune cells the disease is a medical condition selected from the group consisting of a malignancy, an autoimmunc disease and an infectious disease.
21. The method of claim 1 , wherein said hematopoietic cells which are not stem cells and said anti-third party cells having said Tcm phenotype are obtained from the same donor.
22. The method of claim 1 , wherein said anti-third party cells having said Tcm phenotype comprise a CD3 + , CD8 + , CD62L + , CD45RA − , CD45RO + signature.
23. The method of claim 22 , wherein at least 50% of the isolated population of cells are CD3+CD8+ cells of which at least 50% have said signature.
24. The method of claim 1 , further comprising conditioning the subject under sublethal, lethal or supralethal conditioning protocol prior to said administering.
25. The method of claim 1 , wherein said subject is a human subject.
26. The method of claim 1 , wherein said anti-third party cells having said Tcm phenotype are generated by a method comprising:
(a) contacting peripheral blood mononuclear cells (PBMCs) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and
(b) culturing said cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 so as to allow proliferation of cells comprising said central memory T-lymphocyte (Tcm) anti-third party phenotype, thereby generating the anti-third party cells having said Tcm phenotype.
27. The method of claim 26 , further comprising depleting adherent cells from said PBMCs prior to said contacting with said third party antigen or antigens.
28. The method, of claim 26 , further comprising depleting CD4+ and/or CD56+ cells from said PBMCs prior to said contacting with said third party antigen or antigens.
29. The method of claim 26 , further comprising selecting for activated cells following step (a) and prior to step (b).
30. The method of claim 1 , wherein step (a) and step (b) are carried out concomitantly.
31. The method of claim 1 , wherein step (h) is carried out prior to step (a).